Jubilant Pharmova Ltd - 530019 - USFDA Communication
We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.08-03-2023
08-03-2023
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015, we wish to inform the exchange(s) that the Board of Directors of the Company has through circular resolution dated Tuesday, March 7, 2023, considered and approved the appointment of Mr. Shirish G. Belapure as an Additional Director (Non-Executive, Independent) of the Company effective from March 7, 2023 for a period of 5 years.08-03-2023
Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201514-02-2023
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of earnings conference call for the quarter and nine months ended December 31, 202209-02-2023
Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201509-02-2023
Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation08-02-2023
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Financial Results04-02-2023
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Appointment of Statutory Auditors04-02-2023
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Link of Audio recording of investors conference call03-02-2023
Q3FY23 Quarterly Result Announced for Jubilant Pharmova Ltd.
Jubilant Pharmova announced Q3FY23 results: Consolidated Q3FY23: Revenues were at Rs 1,553 crore vs Rs 1,311 crore in Q3FY22 and Rs 1,600 crore in Q2FY23. Reported EBITDA was at Rs 155 crore vs Rs 200 crore in Q3FY22 and Rs 232 crore in Q2FY23. In Q3FY23, we witnessed nil COVID-related deals vs Rs 89 crore in Q3FY22 and Rs 22 Crore in Q2FY22. Finance cost was at Rs 51 crore vs Rs 37 crore in Q3FY22 and Rs 42 crore in Q2FY23. Higher finance cost was on account of the increase in global interest rate benchmarks. 1M SOFR has increased from 3.05% in Q2FY23 to 4.36% in Q3FY23. Reported PAT was at –ve Rs 16 crore as compared with Rs 51 crore in Q3FY22 and Rs 5 crore in Q2FY23. EPS was at –ve Rs 0.98 vs. Rs 3.2 in Q3FY22 and Rs 0.34 in Q2FY23. Capital expenditure for the quarter was Rs 218 crore. Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “During the quarter, the Company reported higher revenues YoY led by an increase in sales in Radiopharmacies, Allergy and CDMO-API businesses and stable revenues in Radiopharmaceuticals, CDMO Sterile Injectables and Drug Discovery Services businesses. The company’s profitability stood lower in Q3FY23 vs. YoY and QoQ due to lower Covid-related deals in the CDMO Sterile Injectables business, industry-wide issue of generator supply outage that impacted Radiopharmacies business, lower production in the CDMO-API business and lower volumes in Drug Discovery Services business. In Generics, the Company has undertaken a large-scale business transformation focused on turnaround through cost optimisations and driving growth in branded markets in India and select international markets. In FY24, Company’s profitability is expected to improve driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in Generics, API businesses and Radiopharmacies will also contribute to better profitability. The Company has several growth levers across its various businesses (Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics and CRDMO), which shall drive sustainable growth for the company in the medium term. In our Proprietary Novel Drugs business, we have several high potential programs, which are at the preclinical/clinical stage.” Result PDF03-02-2023